Altria’s oral tobacco growth softens impact of broader declines in H1 2025

Altria reported a mixed first half of 2025, with overall declines tempered by the strong performance of its oral tobacco products segment – a substantial driver of growth in the second quarter.

During the presentation of its first-half results, the company said its net revenue decreased slightly by 3.6% to $11.4bn in the first six months of 2025, driven by lower net revenues in the smokeable products segment. In the second quarter, the company’s revenue fell by 1.7% to $6.1bn. However, revenue in the oral tobacco segment increased by 3.3% and 5.9% in the first half of the year and second quarter, respectively.

Antonia Di Lorenzo

Newsdesk editor/EU lead reporter
Antonia is a member of the editorial team and holds a masters degree in Law from the University of Naples Federico II, Italy. She moved in 2013 to London, where she completed a postgraduate course at the London School of Journalism. In the UK, she worked as a news reporter for a financial newswire and a magazine before moving to Barcelona in 2019.

Our Key Benefits

The global novel nicotine market is in an opaque regulatory environment that requires professionals to be on top of industry developments to make informed decisions and optimise their strategy.

TobaccoIntelligence provides organisations with leading market and regulatory data analysis to anticipate and understand market developments globally and the impact of regulatory changes to the business.

  • Stay informed of any legal and market change in the sector that impacts your organisation
  • Maximise resources by getting market and legal data analysis daily in one place
  • Make smart decisions by understanding how the regulatory and market landscape evolves
  • Anticipate risks in your decisions by monitoring regulatory changes that impact your organisation